CORREIA ALMEIDA IGOR (BR)
COVAS DIMAS TADEU (BR)
RAJA GABAGLIA TRAVASSOS LUIZ R (BR)
CORREIA ALMEIDA IGOR (BR)
COVAS DIMAS TADEU (BR)
| 1. | Process of preparation and utilization of antigens of Trypanosoma Cruzi, characterized by the fact that EpEx antigen is prepared from epimastigote forms of T. Cruzi, Tulahuén strain, the parasites thereof having been cultured at a temperature of about 28°C in Schneider's insect culture medium containing about 20% fetal calf serum, and wherein after 710 days, the parasites are collected from the culture supernatant, washed 35 times with phosphatebuffered saline at about 100 mM, at a pH of 7.37.4 and centrifuged at 12,00014,000g for 30 45 minutes, at 48°C and the parasites being thereafter immediately resuspended in a TrisHCl buffer at about 10 mM, pH of 7.47.5, containing about o. 20.4 mM leupeptin, about 23 mM ETDA, about 1% nonanoylN methylglucamide, and being submitted to 46 cycles of freezing and thawing, in liquid nitrogen and waterbath (about 37°C), respectively, the resultant lysate being centrifuged at 10,00012,000g for 510 minutes, at about 48°C, and the supernatant, containing the EpEx antigenic preparation, being removed and stored at70°C until the time of use. |
| 2. | Process, according to in claim 1, characterized by the the fatc that the pH of the phosphatebuffered saline is 7.4. |
| 3. | Process, according to claim 1 or 2, characterized by the fact that the washed parasites are centrifuged at 12,000g for 30 minutes, at 4°C. |
| 4. | Process, according to claims 1 to 3, characterized in that the TrisHCl buffer has a pH of 7.5, with 0.2 mM leupeptin, 2 mM ETDA, and 1 % nonanoylN methylglucamide. |
| 5. | Process, according to claims 1 to 4, characterized in that the resuspended parasites are submitted to four cycles of freezing and thawing. |
| 6. | Process, according to claim 5, characterized in that the resultant lysate is centrifuged at 10,000g for 5 minutes at 4°C. |
| 7. | Test for the diagnosis of Chaga's disease, characterized in that 1 100 nanograms of A&T antigen and 40100 nanograms of EpEx antigen, both 11 diluted in 50100 mM carbonatebicarbonate buffer, with a pH of 9.49.6, are added, separately, in white opaque wells of ELISA 96well polystyrene test plates, and after 1218 hours at 48°C, or 24 hours at 3037°C, the plates are washed 35 times with 0.15 mM phosphatebuffered saline, with a pH of 7.3 7.5, containing 0.050,1% Tween 20 (PBST Buffer) and the free sites in the plates are blocked with 0.10.2% bovine serum albumin (BSA) in 50100 mM sodium carbonatebicarbonate buffer, with a pH of 9.49.6, for 1224 hours at 4°C or, alternatively, for 14 hours at 3537°C, the plates being washed 35 times with 300 ml of PBST buffer, and 50100 ml of the sera, diluted 1: 2,000 in PBST buffer containing 0.10.5% BSA (PBSTB buffer), being added in each well; there following the incubation for 30 min. at 3537°C, or 1 hour at 22 28°C, the plates being washed with PBST and the excess liquid being removed by inversion thereof on filter paper and thereafter, 50100 ml of the biotinylated antihuman IgG conjugate, diluted 1: 2,000 in PBSTB buffer is added into each well and the plates being incubated for 530 min. at 3537°C, or 1 hour at 22 28°C, being thereafter washed 35 times with 300 ml of PBST, the excess liquid being removed by inversion on filter paper and 50100 ml of streptavidin horseradish peroxidase conjugate diluted 1: 1,0001: 2,000 in PBST buffer being added into each well, the plates being incubated for 30 min. at 3537°C, or 1 hour at 2228°C, and the plates being washed 35 times with 300 ml of PBST buffer, the excess liquid being removed by inversion on filter paper, followed by incubation of the plates for 530 min. at 2228°C with the reagent Luminol@, diluted 1: 101: 20 in 50100 mM carbonatebicarbonate buffer, with a pH of 9.69.8 or, alternatively, diluted 1: 51: 10 in the same buffer containing 0.1 0.2% skimmed milk, the reaction being quantified using a luminometer for 96 well plate readings, and the results being expressed as Relative Luminescent Units (RLU). |
| 8. | Test, according to claim 7, characterized in that the cutoff value for each test plate, in the reaction of CLELISA with A&T or EpEx, is calculated using the following formula: Plate cutoff value = (NC meanB mean) x 10_ where: NC mean = mean of the readings (RLU's) of negative control serum (at least 4 determinations per plate); B mean = mean of the readings (RLU's) of white (at least 4 determinations per plate), that is, of the reaction in the absence of serum. |
| 9. | Test, according to claim 7, characterized in that 10 nanograms of A&T antigen and 4080 nanograms of EpEx antigen separately in plates are used. |
| 10. | Test, according to claims 7 to 9, characterized in that the ELISA plates are incubated for 12 hours at 4°C and washed 5 times with phosphatebuffered saline. |
| 11. | Test, according to claim 10, characterized in that the phosphate buffered saline has a concentration of 0.15 mM and a pH of 7.5 with o. 05% Tween 20. |
| 12. | Test, according to claims 7 to 11, characterized in that the free sites in the plates are blocked with 0.1% bovine serum albumin (BSA) in 50 mM sodium carbonatebicarbonate buffer, with a pH of 9.6, for 12 hours at 4°C. |
| 13. | Test, according to claim 12, characterized in that the time is fo 2 hours and the temperature is 37°C. |
| 14. | Test, according to claims 7 to 13, characterized in that the plates are washed 5 times with 300 ml of the PBST buffer. |
| 15. | Test, according to claim 14, characterized in that, into each well 50 ml of the sera, containing 0.5% BSA (PBSTB buffer), are added. |
| 16. | Test, according to claims 7 to 15, characterized in that it includes the incubation for 30 min. at 37°C. |
| 17. | Test, according to claims 7 to 16, characterized in that into each well 50 ml of the biotinylated antihuman IgG conjugate are added, and the plates are incubated for 30 min. at 37°C. |
| 18. | Test, according to claims 7 to 17, characterized in that 5 washing operations with 300 ml of PBST are carried out, the excess liquid being removed by inversion on filter paper and 50 ml of streptavidinperoxidase conjugate diluted 1: 1,000 in PBST buffer being added into each well and the plate being incubated for 530 min. at 3537°C, or 1 hour at 2228°C. The plates are washed 35 times with 300 ml of PBST buffer, the excess liquid being removed by inversion on filter paper, and being thereafter incubated for 30 min. at the ambient temperature with the reagent Luminol@, diluted 1: 20 in 50 mM carbonate bicarbonate buffer with a pH of 9.6. |
| 19. | Test, according to claim 18, characterized in that the reagent Luminol0 is diluted 1: 5 in the same buffer containing 0.10.2% skimmed milk. |
Chagas'disease is an endemic disease caused by the flagellate Trypanosoma cruzi. In Latin America, approximately 16 to 18 million individuals are already infected and as many as 90 million individuals are at risk of infection (W. H. O., 1991). The disease is transmitted in Nature by Triatominae vectors. As a result of effective public health measures for the control of the vector in most countries. blood transfusion is quantitatively the most important form of transmission of the disease today. In Latin America, blood samples with antibodies associated with Chagas'disease represent 1-4% of the total blood samples in major Hemocenters.
More recently, Chagas'disease has also become a major public health concern in North America, owing to the increasing number of immigrants from Latin American countries, in the last decade. Recent studies estimate that there may be in the United States approximately 100,000 Trypanosoma cruzi-infected individuals with potential risk of transmitting Chagas'disease by blood transfusion (Hagar and Rahimtoola, 1991).
The diagnosis of acute Chagas'disease is not a problem because of the large number of parasites in the blood. In contrast, the chronic phase is diagnosed by serological methods because of the very small number or absence of circulating parasites. This has also restricted so far the use of polymerase chain reaction (PCR) with specific primers, as the final diagnostic test of Chagas'disease, before a major epidemiologic survey of sera from chronic patients is carried out. The three serological methods that are currently being used in blood banks- hemmagglutination (HA), indirect immunofluorescence (IIF) and enzyme-linked
immunosorbent assay (ELISA)-utilize mixtures of antigens prepared from the epimastigote form of the parasite. According to the World Health Organization (WHO), at least two positive tests of the three cited above are necessary for the diagnosis of the disease. Blood samples that are positive to only one of the three tests are classified as"indeterminate or inconclusive"and, in consequence, discarded. The indeterminate diagnosis is associated with 20 to 90% of all blood samples that gave one or more positive tests for Chagas'disease, depending on the methods employed and how they are applied. This high percentage of indeterminate results represents a serious problem in blood banks, both in terms of volume of discarded blood and doubtful diagnosis of Chagas'disease. In fact, a blood sample with a false positive test is no longer used for transfusion or isolation of cells and other blood components. Such loss of donated blood also affects the production of blood derivatives such as albumin, immunoglobulins and clotting factors which are of commercial value. Conversely, a blood sample with a false negative test is a dangerous source of contamination by the parasite.
The disadvantages of the current serological methods can be summarized as follows: 1. Low sensitivity: current methods use human sera at low dilutions, with a consequent increase in the background due to the cross-reactivity with natural antibodies and low-titer antibodies resulting from nonspecific polyclonal activation. Specific recombinant or synthetic epimastigote antigens, singly or in mixtures, are not sufficiently sensitive because they react only with a limited number of specific antibodies present in the sera of chronic Chagasic patient.
2. Low specificity: serological tests using epimastigote extracts cross-react with antigens from microbial sources other than Trypanosoma cruzi, notably Leishmania and some fungal and bacterial antigens.
Brief Summary of invention The invention describes the purification of the A&T and EpEx antigens, and their use in a chemiluminescent enzyme-linked immunosorbent assay (CL-
ELISA), for the accurate diagnosis of Chagas'disease. When carried out in parallel, the results of the tests taken together provide high sensitivity and high specificity not obtainable with conventional methods described in the literature and/or which are commercially available.
Detailed description of the invention Purification of the A&T antigen A&T antigen is purified from trypomastigote forms of Trypanosoma cruzi according to Almeida et al., 1993 and Almeida et al., 1994a. Trypomastigote forms are obtained from infected green monkey kidney fibroblasts (LLC-MK2 cells) cultured in Dulbecco's modified Eagle medium (D-MEM) containing 10% fetal bovine serum. The cell-derived trypomastigotes are collected 6-7 days later, following their release from infected cells, from the top fluid after sedimentation of the cell debris and incubation for 1.5 h at 37°C. Parasites are washed 3 times in 0.15 M phosphate-buffered saline (PBS), pH 7.4, centrifuged at 12,000g, and kept at-70°C until lyophilization. Lyophilized trypomastigotes are sequentially extracted 5 times with 10 volumes of chloroform/methanol (2: 1), chloroform/methanol (1: 2), chloroform/methanol/water (10: 20: 8), for 30 min each time, at room temperature. After centrifugation at 12,000g, the organic extracts are discarded and the final delipidated pellet is dried under a stream of nitrogen.
The dry pellet is then extracted 5 times with 10 volumes of 9% 1-butanol for 2 h each time, at room temperature. The soluble extract corresponds to the fraction containing at A&T antigen together with some hydrophilic and hydrophobic contaminants. The A&T-containing fraction is then lyophilized for 24 h and chromatographed on a column of octyl-Sepharose (Pharmacia-LKB, Upsala, <BR> <BR> <BR> <BR> Sweden), pre-equilibrated with 5% 1-propanol in 0.1 M ammonium acetate buffer, pH 7.2. The A&T-containing fraction dissolved in 5% 1-propanol in 0.1 M ammonium acetate buffer, pH 7.2 is applied to the column at a low flow rate. The colum is washed with 5% 1-propanol in 0.1 M ammoniun acetate buffer, pH 7.2 and eluted with a 1-propanol gradient (5-60%). The column fractions containing
the A&T antigen are tested for immunoreactivity with a specific polyclonal antibody generated against the A&T antigen (anti-A&T antibody). The A&T- positive fractions from the octyl-Sepharose column are pooled, dried and partitioned between water and 1-butanol. The aqueous phase is lyophilized for 24 h, resuspended in 5% 1-propanol in ammonium acetate 0.1 M, pH 7.2 and applied to the phenyl-Superose column (Pharmacia-LKB, Sweden) (pre-equilibrated with 5% 1-propanol in ammonium acetate 0.1 M, pH 7.2). The column is eluted with a 1-propanol gradient (5-60%). Material eluting in earlier fractions (column void) and containing the A&T antigen is pooled and lyophilized for 24 h. The material included in the column is basically constituted of hydrophobic contaminants, mainly phospholipids. Finally, as a final purification step to eliminate hydrophilic contaminants, A&T antigenic preparation is re-applied to a column of octyl- Sepharose (Pharmacia-LKB, Sweden), pre-equilibrated with 5% 1-propanol in O. 1M ammonium acetate buffer, pH 7.2. The A&T-containing fraction dissolved in 5% 1-propanol in 0.1 M ammonium acetate buffer, pH 7.2 is applied to the column at a low flow rate. The column is washed with 5% 1-propanol in 0.1 M ammonium acetate buffer, pH 7.2 and eluted with a 1-propanol gradient (5-70%) and eluted with a shallow 1-propanol gradient (20-40%). The fractions are assayed for immunoreactivity with the anti-A&T antibody by dot-blotting and Western-blotting. Antibody binding fractions are pooled, exhaustively dialyzed against deionized water, lyophilized for 48 h, redissolved in deionized water and stored at-70°C.
Purification of the EpEx antigen EpEx antigen is prepared from epimastigote forms of Trypanosoma cruzi, Tulahuén strain. Parasites are cultured at 28°C, in Schneider's insect medium containing 20% fetal calf serum. After 7-10 days, the parasites are collected from the culture supernatant, washed three times with 100 mM phosphate-buffered saline, pH 7.4 and centrifuged at 12,000g for 30 min, at 4°C. Pelleted parasites are immediately resuspended in 10 mM Tris-HCI buffer, pH 7.5,0.2 mM
leupeptin, 2 mM EDTA, 1% nonanoyl-N-methylglucamide (lysis buffer), and submitted to four cycles of freezing and thawing, in liquid nitrogen and water- bath (37°C), respectively. The resulting lysate is centrifuged at 10,000g for 5 min, at 4°C. The supernatant, containing the EpEx antigenic preparation, is removed and stored at-70°C.
Chemiluminescent enzyme-linked immunosorbent assay (CL-ELISA) using EpEx and A&T antigens Chemiluminescent ELISA is carried out according to protocols previously described (Almeida et al., 1993,1994b). A&T (at 0.151lg dry weight/jil deionized water) and EpEx (at 0.15ig protein/lll of lysis buffer) antigens are diluted in 50 mM sodium carbonate buffer, pH 9.6, for a final concentration of 0.2 ng/l and 0.8 ng/p, l, respectively. Fifty microliters of each antigen are separately added to each well of milky-white 96-well Maxisorp FluoroNunc plates (Nunc, Denmark).
After 12 h at 4°C, plates are washed 5 times with 0.15 M phosphate-buffered saline, pH 7.4,0.05% Tween 20 (PBS-T) and blocked with 0.1% bovine serum albumin (BSA) in 50 mM sodium carbonate buffer, pH 9.6, for 12 h at 4°C or, alternatively, for 2 h at 37°C. Plates are then washed 5 times with 0.15 M phosphate-buffered saline, pH 7.4,0.05% Tween 20 (PBS-T). The human sera, diluted 1: 2,000 in PBS-T containing 0.5% BSA (PBS-TB), are added to the plates and incubated for 30 min at 37°C. Plates are washed 5 times with PBS-T, the excess liquid removed by inversion or filter paper, and then incubated with biotinylated goat anti-human IgG (Amersham, UK), diluted 1: 2,000 with PBS-TB, for 30 min at 37°C. After washing 5 times with PBS-T, a streptavidin-horseradish peroxidase conjugate (Amersham, UK) diluted 1: 1,000 with PBS-TB is added, following incubation for 30 min at 37°C. Plates are washed 5 times with PBS-T, the excess liquid removed by inversion on filter paper, and then incubated with luminol (ECL reagents, Amersham, UK), diluted 1: 20 in 50 mM carbonate buffer, pH 9.6, for 1-5 min at room temperature. Thereafter, the reaction is quantified
using a luminometer for 96-well polysterene plate readings. The results are expressed as relative luminescent units (RLU). Cutoff values for A&T and EpEx CL-ELISAs were first calculated by determining the reactivities of 200 normal human sera (NHS). The mean and SD of these 200 reactivities were determined. A value of 10 times the SD was added to the mean for the cutoff value,. The dispersion of the RLU readings for 200 NHS showed SD very close to the means using both A&T and EpEx CL-ELISAs (143 + 123 and 177 + 151, respectively).
Therefore, for each plate in which a single negative control (pool of 100 NHS) in quadruplicate was included, the cutoff values for A&T and EpEx CL-ELISA were established as 10 times the negative control mean minus the background control mean (cutoff value = 10 x negative control mean-background control mean).
Result interpretation : To interpret the results obtained, the luminometer reading of a serum sample is divided by the predeterminated cutoff value. A positive result is defined when the relative serum reading (RLU) is greater than 1, which represents the cutoff value. Conversely, a negative sample has an RLU equal or lower than 1.
1. The high sensitivity of the chemiluminescent (CL)-ELISA method permits the use of high dilutions of sera (1: 2,000) (Fig. 1), and thus eliminates most of the nonspecific or false-positive reactions of current methods, which use serum dilutions in the 1: 30 to 1: 400 range (Tables 1 and 2).
Table 1-Comparison between CL-ELISA (with A&T and EpEx) and conventional diagnostic tests with a panel of sera with inconclusive serology for Chagas' disease.
Serum Number of sera Number of sera Diagnostic test dilution Negative Inconclusive Positive False-Negative False-Positive' Chemiluminescence A&T-CL-ELISA2 1: 2,000 74 0 26 0 0 EpEx-CL-ELISA 1: 2,000 72 0 28 0 2 Westem blotting-EpEx 1: 400 72 11 17 0 2 ELISA-EpEx 1: 100 77 7 16 3 0 Commercial kits ELISA-A1 1: 41 10 70 20 0 64 ELISA-A2 1: 41 41 21 38 0 33 ELISA-B 1: 41 67 8 25 0 7 ELISA-C 1: 41 69 17 14 0 5 HA 1: 40 79 12 9 5 0<BR> IF 1: 30 79 6 15 5<BR> <BR> No. Of false-positive sera = [no. Of positive + inconclusive sera with each test]-no. Of positive sera with the reference method<BR> (A&T-CL-ELISA).
2 CL-ELISA with A&T antigen (CLE-A&T) is considered the gold method.
Table 2-CL-ELISA reactivity of A&T and EpEx antigens with inconclusive and heterologous sera.
Reactive sera in Number Conventional CL-ELISA <BR> <BR> Conventional serology of sera tests'A&T EpEx<BR> <BR> InconclusiveforChagas disease 100 100 26 28 Leishmaniasis visceral 11 5 0 2 cutaneous 16 10 0 1 Autolmmune diseases 30 0 0 0 Infectious diseases AIDS 24 0 0 0 Hepatitis 24 0 0 0 Syphilis 24 0 0 0 Paracoccidioidomycosis 5 1 0 0 Poli A/C vaccinated (Neisseriameningitidis) pre-immune 5 0 0 0 Immunized 5 5 0 0 Chagas'disease 100 100 100 100 Normal human sera 200 0 0 0 Number of sera giving at least 1 positive reaction in the conventional Chagas'disease serology (indirect immunofluorescence, indirect hemagglutination and ELISA).
2 Two reactions with EpEx are false-positive.
2. The A&T antigen is a purified preparation of closely related molecules thar are specific of the trypomastigote stage obtained in tissue culture of mammalian
cells, thus being very similar to the infective forms of the parasite that cause the disease in man.
3. Since the serological reactions with A&T antigen are highly specific, there is no cross-reactivity with antigens from a variety of other infectious agents including Leishmania, and with natural antibodies and low-titer antibodies resulting from nonspecific polyclonal activation (Table 2).
4. The A&T antigen is easily obtainable in amounts sufficient for a great number of tests in appropriate ELISA plates for chemiluminescent reading. Moreover, the purified A&T antigen is highly stable when fixed on plates for prolonged periods.
5. Since A&T antigen reacts with lytic (protective) antibodies, characteristic of active infection and present in high titers in chronic patient sera, it can be used to monitor the response of patients to chemotherapy (Fig. 2).
6. The EpEx complex antigen is prepared from the epimastigote form and contains many components that are also expressed in the infective stage. It reacts with antibodies that are recognized by conventional serology for Chagas'disease, but not with those antibodies whose reactions are due to artifacts such as blocking reagents, culture medium supplements, etc.
7. The EpEx antigen is readily prepared from fast growing epimastigote culture, and although it is not as specific as A&T purified antigen, it is highly sensitive and provide complementary and confirmatory data for the positive reactions obtained with A&T antigen (Fig. 1).
8. The advantages of using both A&T and EpEx antigens in parallel tests are the following: a) the antigens present in both tests are highly sensitive and therefore, a positive result with both antigens provides a diagnosis with a high level of confidence (Fig. 1, Table 1); b) positive reactivity with EpEx, and negative with A&T, while eliminating active Chagas'infection, suggests leishmaniasis or another infectious disease (Table 2);
c) a decrease in the reactivity with A&T followed by a decrease with EpEx has prognostic value, and is a criterion of cure in patients submitted to chemotherapy (Fig. 2); d) when applied to sera classified as"indeterminate" (i. e. sera which are negative to one or two of the following tests: hemagglutination, immunofluorescence and ELISA), the A&T and EpEx tests provide unambiguous results, thereby eliminating inconclusive serological diagnosis of Chagas'disease (Tables 1 and 2)
REFERENCES World Health Organization (1991) Control of Chagas'disease. WHO Tech. Rep.
Ser.
811: 1-91 Hagar, J. M and Rahimtoola, S. H. (1991) Chagas'heart disease in the United States. N. Engl. J. Med. 325: 763-8 Almeida, I. C., Krautz, G. M., Krettli, A. U. and Travassos, L. R. (1993) Glyconjugates of Trypanosoma cruzi: a 74 kD antigen of trypomastigotes specifically reacts with lytic anti a galactosyl antibodies from patients with chronic Chagas disease. J. Clin. Lab. Anal. 7: 307-316.
Almeida, I. C., Ferguson, M. A. J., Schenkman, S. and Travassos, L. R.
(1994a). Lytic anti-a-galactosyl antibodies from patients with chronic Chagas disease recognise novel O-linked oligosaccharides on mucin-like GPI-anchored glycoproteins of Trypanosoma cruzi. Biochem. J. 304: 793-802.
Almeida, I. C., Rodrigues, E. G. and Travassos, L. R. (1994b) Chemiluminescent immunoassays: discrimination between the reactivities of natural and human patient antibodies with antigens from eukaryotic pathogens, Trypanosoma cruzi and Paracocidioides brasiliensis. J. Clin. Lab. Anal. 8: 424-431.